By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Horizon Pharma plc 

Connaught House, 1st Floor
1 Burlington Road
Dublin 4      Ireland
Phone: +353-1-72-2100 Fax:


SEARCH JOBS








Company News
Horizon Pharma (HZNP) Announces Health Canada Approval Of PROCYSBI (Cysteamine Delayed-Release Capsules) For The Treatment Of Nephropathic Cystinosis 6/19/2017 8:34:27 AM
Horizon Pharma (HZNP) Release: Epidemiologic Study Findings Show Over 400 Percent Increase In Gout Patient Hospitalizations Since 1993 6/14/2017 12:20:47 PM
Horizon Pharma (HZNP) Presents New Data Analyses Further Demonstrating Clinical Benefit Of KRYSTEXXA (Pegloticase) In Patients With Uncontrolled Gout 6/14/2017 11:57:14 AM
Horizon Pharma (HZNP) Pays $145 Million For River Vision And Its Rare Eye Disease Drug 5/8/2017 6:04:43 AM
Horizon Pharma (HZNP) To Present Data On RAVICTI (Glycerol Phenylbutyrate) Oral Liquid For Urea Cycle Disorder Patients Aged Two Months To Two Years 3/22/2017 8:51:33 AM
Horizon Pharma (HZNP) Release: Global Genes And Company Partner To Offer Nephropathic Cystinosis Scholarships 1/18/2017 10:16:39 AM
Horizon Pharma (HZNP) Craters as Rare Neuromuscular Drug Flunks Late-Stage Study 12/8/2016 5:42:02 AM
Sobi And Horizon Pharma (HZNP) Enter Five-Year Distribution Agreement For Ravicti And Ammonaps Outside The United States 12/7/2016 7:31:46 AM
Horizon Pharma (HZNP) Presents Data On KRYSTEXXA (Pegloticase) For The Management Of Refractory Chronic Gout At The 2016 ACR/ARHP Annual Meeting 11/14/2016 8:13:32 AM
Horizon Pharma (HZNP) Announces Third-Quarter 2016 Financial Results 11/7/2016 8:23:55 AM
12345678910...
//-->